Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial
…, M Marko, N Singh, S Wasyliw, K Ryckborst, C Kenney… - The Lancet, 2020 - thelancet.com
Background Nerinetide, an eicosapeptide that interferes with post-synaptic density protein
95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. …
95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. …
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised …
…, C Doram, A Ademola, M Shamy, C Kenney… - The Lancet, 2022 - thelancet.com
Background Intravenous thrombolysis with alteplase bolus followed by infusion is a global
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …
Tenecteplase–tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion
SB Coutts, V Dubuc, J Mandzia, C Kenney… - Stroke, 2015 - Am Heart Assoc
Background and Purpose— Minor stroke and transient ischemic attack with an intracranial
occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK–…
occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK–…
Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial
…, S Jamieson, V Karnik, C Kenney… - … Open Access Journal, 2021 - cmajopen.ca
Background: Identification of therapies to prevent severe COVID-19 remains a priority. We
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …
Assessment of discrepancies between follow-up infarct volume and 90-day outcomes among patients with ischemic stroke who received endovascular therapy
…, N Singh, S Wasyliw, KJ Ryckborst, C Kenney… - JAMA network …, 2021 - jamanetwork.com
Importance Some patients have poor outcomes despite small infarcts after endovascular
therapy (EVT), while others with large infarcts do well. Understanding why these discrepancies …
therapy (EVT), while others with large infarcts do well. Understanding why these discrepancies …
Ethical justification for deferral of consent in the AcT trial for acute ischemic stroke
H Faris, B Dewar, D Dowlatshahi, A Ramji, C Kenney… - Stroke, 2022 - Am Heart Assoc
The AcT trial (Alteplase Compared to Tenecteplase) compares alteplase or tenecteplase for
patients with acute ischemic stroke. All eligible patients are enrolled by deferral of consent. …
patients with acute ischemic stroke. All eligible patients are enrolled by deferral of consent. …
Alteplase compared to tenecteplase in patients with acute ischemic stroke (AcT) trial: protocol for a pragmatic registry linked randomized clinical trial
Background: Intravenous thrombolysis with alteplase is widely used in acute ischemic stroke
patients presenting early after symptom onset. Recent phase II trials have suggested that …
patients presenting early after symptom onset. Recent phase II trials have suggested that …
Mediation of Age and Thrombectomy Outcome by Neuroimaging Markers of Frailty in Patients With Stroke
…, S Wasyliw, KJ Ryckborst, C Kenney… - JAMA Network …, 2024 - jamanetwork.com
Importance Age is a leading predictor of poor outcomes after brain injuries like stroke. The
extent to which age is associated with preexisting burdens of brain changes, visible on …
extent to which age is associated with preexisting burdens of brain changes, visible on …
Act trial: protocol for a pragmatic Registry‐Linked randomized clinical trial
Background Intravenous thrombolysis with alteplase is widely used in patients with acute
ischemic stroke presenting early after symptom onset. Recent phase II trials have suggested …
ischemic stroke presenting early after symptom onset. Recent phase II trials have suggested …
Tissue Window in Stroke Thrombolysis study (TWIST): a safety study
MD Hill, C Kenney, I Dzialowski… - Canadian journal of …, 2013 - cambridge.org
Master layout sheet Page 1 Current thrombolytic therapy is limited by the number of patients
who arrive both in time for therapy and with a known time of onset. In the Registry of the …
who arrive both in time for therapy and with a known time of onset. In the Registry of the …